Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas.

Francis JH, Milman T, Grossniklaus H, Albert D, Folberg R, Levitin G, Coupland S, Catalanotti F, Rabady D, Kandoth C, Busam K, Abramson D.

Ophthalmology. 2019 May;126(5):759-763. doi: 10.1016/j.ophtha.2018.12.011. Epub 2018 Dec 8.


Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma.

Francis JH, Catalanotti F, Landa J, Barker CA, Shoushtari AN, Abramson DH.

Br J Ophthalmol. 2019 Sep;103(9):1266-1271. doi: 10.1136/bjophthalmol-2018-312612. Epub 2018 Oct 31.


Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds.

Abramson DH, Ji X, Francis JH, Catalanotti F, Brodie SE, Habib L.

Br J Ophthalmol. 2019 Apr;103(4):488-493. doi: 10.1136/bjophthalmol-2018-312037. Epub 2018 Jun 6.


Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery.

Akella SS, Francis JH, Knezevic A, Ostrovnaya I, Gobin YP, Friedman D, Guarini E, Eibeler L, Catalanotti F, Abramson DH.

PLoS One. 2018 May 7;13(5):e0197052. doi: 10.1371/journal.pone.0197052. eCollection 2018.



Francis JH, Abramson DH, Habib L, Yannuzzi LA, Catalanotti F.

Ophthalmology. 2018 Apr;125(4):e31. doi: 10.1016/j.ophtha.2017.11.002. No abstract available.


Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma.

Abramson DH, Catalanotti F, Brodie SE, Kellick MG, Francis JH.

Ophthalmic Genet. 2018 Jun;39(3):353-356. doi: 10.1080/13816810.2018.1443343. Epub 2018 Mar 7.


Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.

Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.


A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub T, Lacouture ME, Carvajal RD, Panageas KS, Berger MF, Rosen N, Solit DB, Chapman PB.

Oncologist. 2015 Jul;20(7):789-97. doi: 10.1634/theoncologist.2014-0012. Epub 2015 May 8.


MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance.

Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M.

Mol Cell. 2013 Apr 11;50(1):43-55. doi: 10.1016/j.molcel.2013.01.037. Epub 2013 Feb 28.


Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB.

Clin Cancer Res. 2013 Apr 15;19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476. Epub 2013 Feb 26.


Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?

Catalanotti F, Solit DB.

Clin Cancer Res. 2012 May 1;18(9):2420-2. doi: 10.1158/1078-0432.CCR-12-0626. Epub 2012 Mar 22.


A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.

Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M.

Nat Struct Mol Biol. 2009 Mar;16(3):294-303. doi: 10.1038/nsmb.1564. Epub 2009 Feb 15.


Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development.

Galabova-Kovacs G, Catalanotti F, Matzen D, Reyes GX, Zezula J, Herbst R, Silva A, Walter I, Baccarini M.

J Cell Biol. 2008 Mar 10;180(5):947-55. doi: 10.1083/jcb.200709069.


Direct effects of polymyxin B on human dendritic cells maturation. The role of IkappaB-alpha/NF-kappaB and ERK1/2 pathways and adhesion.

Valentinis B, Bianchi A, Zhou D, Cipponi A, Catalanotti F, Russo V, Traversari C.

J Biol Chem. 2005 Apr 8;280(14):14264-71. Epub 2005 Jan 25.


HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA.

EMBO Rep. 2004 Aug;5(8):825-30. Epub 2004 Jul 23.

Supplemental Content

Loading ...
Support Center